Abstracts tagged "Behçet’s Syndrome"

Abstract Number: 0240 • ACR Convergence 2025
Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
Amir Razmjou¹, Alexandra Klomhaus², David Kellner³, Meika Fang⁴, Michael Weisman⁵ and John FitzGerald³, ¹UCLA / Veterans Affairs, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA, Los Angeles, CA, ⁴VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁵Cedars-Sinai Medical Center, LOS ANGELES, CA
Background/Purpose: Behçet’s disease (BD) is a chronic systemic disease with heterogenous clinical presentations. The strongest genetic risk factor and diagnostic biomarker for BD is the…
Abstract Number: 2536 • ACR Convergence 2025
High Levels of Fatigue and Poor Sleep Quality in Behçet’s Disease: a Cross-sectional Study from a Non-endemic Area
Mateus Augusto Rangel Nunes, Carlos Teixeira, Laurie Kumano, Gabriela Gutierrez, Vitor Grotti, Ana Paula Toledo Del Rio, Ibsen Coimbra, Alisson Pugliesi and Zoraida Sachetto, UNICAMP, Campinas, Brazil
Background/Purpose: Behçet's disease (BD) is a chronic systemic inflammatory disease classified as a variable vessel vasculitis of unknown etiology. It is marked by recurrent oral…
Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 2534 • ACR Convergence 2025
Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61
Koichi Sugihara¹, Risa Wakiya², Hiromi Shimada¹, Taichi Miyagi³, Yusuke Ushio³, Mao Mizusaki¹, Kanako Chujo³, Naoto Manabe³, Mayuko Wada¹, Shusaku Nakashima¹ and Hiroaki Dobashi¹, ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University, Ota City Tokyo, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: The associations of HLA-B51 and HLA-A26 with the onset of Behçet’s disease (BD) are well established. Although BD manifests with a variety of clinical…
Abstract Number: 2535 • ACR Convergence 2025
Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region
Ricardo Machado¹, Thales Souza², Matheus França³, Vinicius Matias⁴, Sylvia Farhat¹, Carolina Siqueira⁴, Maria Carolina Santos⁴, Lia Steuer¹, Luisa Forero¹, Rafael Bassara Macedo⁵, Thiago Freitas⁶, barbara Bayeh⁷, Carolina Ejnisman⁸, Pedro Araujo⁹, Rafael Cordeiro¹⁰, Fabio Specian⁵, Verena Balbi¹, Nadia Emi Aikawa¹¹, Katia Kozu¹, Clovis Artur Silva¹², Lucia Maria Campos¹³, Adriana Elias¹⁴ and Henrique Giardini⁶, ¹Instituto da Criança e do Adolescente, Hospital das Clinicas, Sao Paulo, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de Brasilia, Brasilia, Distrito Federal, Brazil, ³Instituto da Criança e do Adolescente, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil, ⁴Faculdade de Ciências Medicas da Santa Casa de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁷Hospital das Clínicas, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil, ⁸Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁹Universidade de São Paulo, Sao Paulo, São Paulo, Brazil, ¹⁰Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ¹¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ¹²University of São Paulo, São Paulo, São Paulo, Brazil, ¹³Instituto da Criança e do Adolescente, São Paulo, São Paulo, Brazil, ¹⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas, University of Sao Paulo Medical School, São Paulo, São Paulo, Brazil
Background/Purpose: Behçet’s syndrome (BS) is a chronic inflammatory disorder characterized by a heterogeneous clinical presentation, occurring primarily in young adults and very rarely in children…
Abstract Number: 2527 • ACR Convergence 2025
Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Eduardo Borba¹, Caio Carvalho², Nadia E Aikawa³, Ana C Medeiros-Ribeiro², Sandra G Pasoto², Carla Saad⁴, Henrique Giardini⁵, Thiago Freitas⁵, Rafael Cordeiro⁶, Eloisa Bonfa¹ and Clovis Artur Silva⁷, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ³Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁷University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Although rare, new-onset Behçet’s syndrome (BS) and disease flares have been reported following vaccination. In this context, the recommendation of the Recombinant Herpes Zoster…
Abstract Number: 2045 • ACR Convergence 2025
Malignancy in Behçet’s Syndrome: A 24-Year Cohort Study In a Non-Endemicand Multiethnic Country
Pedro Araujo¹, Rafael Bassara Macedo², Fabio Specian², Carolina Ejnisman³, Barbara Bayeh³, Percival Sampaio-Barros⁴, Thiago Freitas⁴, Rafael Cordeiro⁵ and Henrique Giardini⁴, ¹Universidade de São Paulo, Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil
Background/Purpose: Behçet’s syndrome (BS) has been associated with an increased risk of malignancy, particularly in studies from endemic regions such as East Asia and the…
Abstract Number: L14 • ACR Convergence 2024
A Withdrawal Study of Colchicine in Behçet Syndrome
Basak Sirin¹, Sinem Nihal Esatoglu², Hasan Yazıcı³ and Gulen Hatemi⁴, ¹Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul, Turkey, ³Academic Hospital, Istanbul, Turkey, ⁴Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul,Türkiye, Istanbul, Turkey
Background/Purpose: Previous randomized controlled studies reported conflicting results regarding the effectiveness of colchicine on oral ulcers in Behçet syndrome (BS). A randomized drug discontinuation design…
Abstract Number: 2515 • ACR Convergence 2024
Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study
Weiyi Xia¹, Jiachen Li¹, Tian Liu¹ and Yuhui Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University, BeiJing, China
Background/Purpose: The aim of this prospective cohort study is to evaluate the efficacy and safety of Janus kinase (JAK) inhibitor upadacitinib in refractory Behçet’s Syndrome…
Abstract Number: 2517 • ACR Convergence 2024
Skin Microbiome Shows Differences Between Pathergy Positive and Negative Patients with Behçet’s Syndrome
Betul Sarac¹, Ayse Kalkanci², Esra Kilic², Elif Ayca Sahin², Yesim Ozguler³ and Gulen Hatemi³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ²Gazi University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Gut, oral and genital mucosa microbiome studies in Behçet’s syndrome have shown heterogeneous results including reduced bacterial diversity and decrease in butyrate-producing bacteria. A…
Abstract Number: 2518 • ACR Convergence 2024
Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype
Yesim Ozguler¹, Olivier Manches², Didar Ucar³, Ziyan Lin², Alireza Khodadadi-Jamayran², Aristotelis Tsirigos², Gulen Hatemi¹ and Johannes Nowatzky⁴, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²NYU Grossman School of Medicine, New York, NY, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…
Abstract Number: 2522 • ACR Convergence 2024
Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event
Kerem Abacar¹, Ayşe Elif Boncukcuoğlu¹, Aysun Aksoy², Derya Kocakaya¹, Çagatay Cimşit¹, Haner Direskeneli³ and Fatma Alibaz Öner³, ¹Marmara University, istanbul, Turkey, ²Alaaddin Keykubat University, Antalya, Turkey, ³Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome.…
Abstract Number: 2524 • ACR Convergence 2024
Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis
Sooah Kim¹, Ye Ji Jung², Joong Kyong Ahn³ and Jiwon Hwang⁴, ¹Environment Science & Biotechnology, Jeonju University, Jeonju, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea, ³Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁴Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea
Background/Purpose: Oral manifestations can be the initial indicators of systemic diseases such as Behcet’s disease (BD) and Sjogren’s syndrome (PSS). The frequency and presentation of…
Abstract Number: 0150 • ACR Convergence 2024
The Characteristics of a Northern Israeli Cohort of Patients with Behcet’s Syndrome
Firas Sabbah¹, Fadi Hassan², Rula Daood², Helana Jeries³, Tamar Hareuveni⁴, Nimer Abed⁵ and Mohammad E Naffaa², ¹Rheumatology Unit, Tzafon Medical Center, Poria, Israel, Tiberias, Israel, ²Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, Israel, ³Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, HaZafon, Israel, ⁴Ophthalmology department, Galilee Medical Center, Naharyia, Israel, Nahariya, Israel, ⁵Internal Medicine "B", Galilee Medical Center, Naharyia, Israel, Nahariya
Background/Purpose: Behcet's syndrome (BS) is a multisystem disease that typically manifests as recurrent oral and genital ulcers, along with skin, eye, gastrointestinal, neurologic and vascular…
Abstract Number: 1111 • ACR Convergence 2024
Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism
Kessiena Aomreore, Lincoln Medical Center, New york, NY
Background/Purpose: Autoimmune diseases are associated with a high prevalence of pulmonary embolism due to the inflammation-induced hyper coagulable state.This study aimed to analyze trends in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].